Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

Published:2014-04-23 Issue:7504 Volume:510 Page:278-282
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Asangani Irfan A.,Dommeti Vijaya L.,Wang Xiaoju,Malik Rohit,Cieslik Marcin,Yang Rendong,Escara-Wilke June,Wilder-Romans Kari,Dhanireddy Sudheer,Engelke Carl,Iyer Mathew K.,Jing Xiaojun,Wu Yi-Mi,Cao Xuhong,Qin Zhaohui S.,Wang Shaomeng,Feng Felix Y.,Chinnaiyan Arul M.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature13229.pdf

Reference42 articles.

1. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010)

2. Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nature Med. 10, 33–39 (2004)

3. Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet. 9, 401–406 (1995)

4. Stein, M. N., Goodin, S. & Dipaola, R. S. Abiraterone in prostate cancer: a new angle to an old problem. Clin. Cancer Res. 18, 1848–1854 (2012)

5. Reid, A. H. et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28, 1489–1495 (2010)

Cited by 801 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel magnetic ligand-based assay for the electrochemical determination of BRD4;Talanta;2024-11

2. NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis;Nature Genetics;2024-09-09

3. Targeted inhibition of BET proteins in HPV16-positive head and neck squamous cell carcinoma reveals heterogeneous transcriptional responses;Frontiers in Oncology;2024-09-05

4. An updated patent review of BRD4 degraders;Expert Opinion on Therapeutic Patents;2024-09-04

5. CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer;British Journal of Cancer;2024-08-08